NEW YORK (GenomeWeb News) – Accelrys today reported a 3 percent increase in revenues for the fourth quarter of its 2008 fiscal year and cut its net loss for the period by half.   
 
Revenue for the quarter ended March 31, 2008, rose to $20.4 million from $19.9 million for the same quarter of the previous year. The company attributed the increase to

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.